

Publications Annette Vangsted:

1. B. Ottesen, B. Pedersen, A.J. Vangsted, P. Rogowski, A.-R. Fuchs, J. Nielsen, D. Dalgaard, B. Bardrum, and J. Fahrenkrug. Oxytocin and vasopressin release by vasoactive intestinal polypeptide (VIP) in normal women. *J. Obstet. Gynecol.* 9: 83-86 (1988).
2. A.R. Fuchs, A.J. Vangsted, M. Ivanisevic, and K. Emarest: Oxytocin Antagonist (dTVT) and Oxytocin Receptors in Myometrium and Decidua. *American J. Perinatology* 6: 205-208 (1989). Selected for publication in *Clinical Digest Series*.
3. P.J. Larsen, M.M.T. O`Hare, A.J. Vangsted, and J.D. Mikkelsen: Gastrin Releasing Peptide (GRP) is present in a GRP (1-27) form in anterior pituitary. *Peptides* 10: 1-4 (1989).
4. A.J. Vangsted and T. Schwartz: Production of Gastrin releasing peptide-(18-27) and a stable fragment of its precursor in small cell lung carcinoma cells. *J. Clin. Endocrinol. Metab.* 70: 1586-1593 (1990).
5. A.-R. Fuchs, O. Behrens, H. Helmer, A.J. Vangsted, M. Ivanisevic, J. Grifo, M. Fields and C. Barros: Oxytocin and vasopressin binding sites in human and bovine ovaries. *American Journal of Obstetrics and Gynecology.* 163: 1961-1967 (1990).
6. A.J. Vangsted, H. Clausen, T. Kjeldsen, T. White, B. Sweeney, S. Hakomori, L. Drivsholm and J. Zeuthen: Immunochemical detection of a Small cell lung cancer-associated ganglioside (FucGM1) antigen in serum. *Cancer Res.* 51: 2879-2884 (1991).
7. A.J. Vangsted, E. Andersen, L. Nedergård Thomsen and J. Zeuthen. Gastrin releasing peptide GRP(14-27) in human breast cancer cells and in small cell lung cancer. *Breast Cancer Res. Treat.* 19: 119-128 (1991).
8. C. Radzikowski, A.J. Vangsted and J. Zeuthen. Differential Expression of cell membrane antigens and tumorigenicity in athymic nude mice of human urothelial cell (cytotoxic sensitivity, (HCV-29) and its v-raf transfected variants. *Contrib. Oncol. Immunodeficient mice in Oncology*, KRAGER Basel, H.H. Fiebig and D.P. Berger, Eds., Vol. 42, 201-245 (1992).
9. C. Geisler, B. Rubin, S. Casper-Bauguil, E. Champagne, A.J. Vangsted and M. Gajhede: Structural mutations of C-domains in membranes of the immunoglobulin superfamily: Consequences for the interactions between the T cell antigen receptor and the CD3- ζ 2 homodimer. *J. Immunol.* 148: 3469-3477 (1992).

10. T. Pallesen, A.J. Vangsted, H. Clausen, L. Drivsholm, J. Zeuthen and H. Wallin. Serum immunoassay of a small cell lung cancer associated ganglioside: Development of a sensitive scintillation proximity assay. *Glycoconjugate J.* 9:331-335 (1992).
11. A.J. Vangsted, A. Neisig, J. Zeuthen and C. Geisler. Induction of CD3- ω chains by phorbol 12-myristate 13-acetate. *Eur. J. Immunology.* 23:1351-1357 (1993).
12. A. Neisig, A.J. Vangsted, J. Zeuthen and C. Geisler. Assembly of the T cell antigen receptor: participation of the CD3 ω chain. *J. Immunol.* 151:870-879 (1993).
13. A.J. Vangsted and J. Zeuthen. Monoclonal antibodies for diagnosis and potential therapy of small cell lung cancer: The ganglioside antigen Fucosyl-GM₁. *Acta Oncologica* 32:845-851 (1993).
14. A.J. Vangsted, L. Drivsholm, E. Andersen T. Pallesen, J. Zeuthen and H. Wallin. Serum markers in small cell lung cancer: New serum markers for small cell lung cancer. I: The ganglioside Fucosyl-GM₁. *Cancer Detection and Prevention.* 18(3):221-229 (1994).
15. A.J. Vangsted, L. Drivsholm, E. Andersen, E. Bock. New serum markers for small cell lung cancer. II: The Neural Cell Adhesion Molecule, NCAM. *Cancer Detection and prevention.* 18(4):291-298 (1994).
16. C. Radzikowski, J. Rygaard, W. Budzynski, J.P. Stenvang, M. Schou, A.J. Vangsted and J. Zeuthen. Strain -and age dependent natural and activated in vitro cytotoxicity in athymic nude mice: *APMIS*, 102:481-488 (1994).
17. L. Drivsholm. A.J. Vangsted, T. Pallesen, H.H. Hansen, P. Dombernowsky, M. Hansen, F. Hirsch, H.H. Hansen. FucGM₁ in small cell lung cancer. A comparison to the tumor marker neuron-specific enolase. *Annals of Oncology* 5:623-626 (1994).
18. A. Vangsted. Serological tumor marker for SCLC and their therapeutic implications. *APMIS*.102:561-580 (1994).
19. A. Vangsted, P. Gimsing, T.W. Klausen, B. A. Nexø, H. Wallin, P. Andersen, P. Hokland, S.T. Lillevang and U. Vogel. Polymorphism in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma undergoing autologous bone marrow transplantation. *Int. J Cancer:* 120, 1036-1045 (2006).
20. A. Vangsted, T. W. Klausen, W. Ruminski, P. Gimsing, N.F. Andersen, A.O. Gang, N. Abildgaard, L.M. Knudsen, J.L. Nielsen, H. Gregersen and U. Vogel. The polymorphism *IL-1 β* T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing Auto-SCT. *Bone Marrow Transplantation:* 43, 539-545, 2009.

21. H. Hasselbalch, H. Birgens, I.H. Dufva, A-M. Dalseg, P. de Nully Brown, M. K Nielsen, A. Vangsted. Nye medicinske behandlingsprincipper inden for hæmatologien. Ugeskrift for læger, 170, 24:2115-2119, 2008.
22. T. Lund, H. Gregersen, P. Marker, A. Vangsted and N. Abildgaard. Bisfosfonat-associeret osteonekrose i kæberne hos patienter med myelomatose. Ugeskrift for læger 171:50-52, 2009.
23. A. Vangsted, T.W. Klausen, P. Gimsing, N.F. Andersen, N. Abildgaard, H. Gregersen and U. Vogel, A Polymorphism in NFKB1 is associated with improved effect of interferon- α maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. Haematologica, 94 (9), 1274-1282, 2009
24. HE Johnsen, LM Knudsen, AK Mylin, P Gimsing, H Gregersen, N Abildgaard, JL Nielsen, N Frost Andersen, T Plesner, A Vangsted, T Mourits-Andersen. Impaired stem cell mobilization by adding fludarabine to cyclophosphamide-dexamethason induction therapy in multiple myeloma patients. Report from the NMSG #13/03 sponsored randomized, placebo controlled trial. Hematology Reviews, vol 1; 62-64. 2009.
25. Annette J. Vangsted Tobias W. Klausen, Niels F. Andersen, Niels Abildgaard, Anne O. Gang, Henrik Gregersen, Ulla Vogel and Peter Gimsing. Improved survival of multiple myeloma with late relapse after high-dose treatment and stem cell support, a population based study of 348 patients in Denmark in 1994-2004. European Journal of Haematology, 85:209-216, 2010.
26. A. O. Gang, U. Gang, A. Apri, A. Vangsted. Early infections in patients undergoing high dose treatment with stem cell support-a single centre investigation of 246 cases. Hematology, 15: 221-228, 2010.
27. A. Vangsted, Karen Sjøbye, Tobias W. Klausen, Niels Abildgaard, Niels F. Andersen, P. Gimsing, H. Gregersen, U. Vogel, Thomas Werge and Henrik Berg Rasmussen. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide and bortezomib in patients with multiple myeloma. BMC Cancer, 2010, 10:404.
28. Peter Gimsing, Kristina Carlson, Ingemar Turesson, Peter Fayers, Anders Waage, Annette J. Vangsted, Anne Mylin, Christian Gluud, Gunnar Juliusson, Henrik Gregersen, Henrik Hjorth Hansen, Ingrid Nesthus, Inger-Marie S. Dahl, Jan Westin, Johan Lanng-Nielsen, Lene Meldgaard Knudsen, Lucia Ahlberg, Martin Hjorth, Niels Abildgaard, Niels Frost Andersen, Olle Linder and Finn Wisløff. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic

Myeloma Study Group): a double-blind, randomized controlled trial. *Lancet Oncology* 2010, 11:973-92.

29. Teh Liane Khoo, Annette Juul Vangsted, Douglas Joshua, John Gibson. Interferon-alpha in the Treatment of Multiple Myeloma . "Interferon-alpha2 in the Treatment of Haematological Malignancies. Status and Perspectives". *Current Drug Targets*, 2011,12(3)437-446.
30. Marie Klinge Brimnes, Annette Juul Vangsted, Lene Meldgaard Knudsen, Peter Gimsing, Anne Ortved Gang, Hans Erik Johnsen, Inge Marie Svane. Increased level of both CD4⁺FOXP3⁺ regulatory T cells and CD14+HLA-DR-/low myeloid derived suppressor cells and decreased level of dendritic cells in multiple myeloma patients. *Scandinavian Journal of Immunology* 2010 72(6):540-7.
31. Annette J. Vangsted, Tobias W. Klausen, Peter Gimsing, Niels Abildgaard, Niels F. Andersen, Henrik Gregersen, Bjørn A. Nexø, and Ulla Vogel. The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment with stem cells support: A linkage disequilibrium mapping in *RAI* and *CD3EAP*. *Annals of Hematology*, 2011,(6):675-84.
32. Annette J. Vangsted, Tobias W. Klausen, Niels Abildgaard, Niels F. Andersen, Peter Gimsing, Henrik Gregersen, Bjørn A. Nexø, and Ulla Vogel. Single nucleotide polymorphisms in the promoter region of the *IL1B* gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib. *Annals of Hematology*, 2011, (10):1173-81.
33. Niels Frost Andersen, Ulla Vogel, Tobias W. Klausen, Peter Gimsing, Henrik Gregersen, Niels Abildgaard, Annette Vangsted. Vascular endothelial growth factor (VEGF) gene polymorphisms influence the efficacy of thalidomide in multiple myeloma. 2012,131(5):E636-42. *Int. J Cancer*, 2012.
34. Hjorth M¹, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG). Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. *Eur J Haematology* 2012, 88 (6) 485-96.
35. Annette J. Vangsted, Tobias W. Klausen and Ulla Vogel. Inborn genetic variations in multiple myeloma and risk of disease. *Eur J Haematol*, 2012, 88(1):8-30.

36. Annette J. Vangsted, Tobias W. Klausen and Ulla Vogel. Inborn genetic variations in multiple myeloma and influence on treatment outcome. *Eur J Haematol.* 2012, 8(2):93-117.
37. Annette J. Vangsted, Kaspar R. Nielsen, Tobias W. Klausen, Einar Haukaas, Anne Tjønneland, Ulla Vogel. A functional polymorphism in the promoter region of the *IL1B* gene is associated with risk of multiple myeloma. *BJH*, 2012, 158(4):515-8.
38. Alessandro Martino, Daniele Campa, Krzysztof Jamrozak, Rui Manuel Reis, Juan Sainz, Gabriele Buda, Ramón García-Sanz, Fabienne Lesueur, Herlander Marques, Victor Moreno, Manuel Jurado, Rafael Ríos, Zofia Szemraj-Rogucka, Janusz Szemraj, Anne Tjønneland, Kim Overvad, Annette Juul Vangsted, Ulla Vogel, Gabor Mikala, Katalin Kádár, Gergely Szombath, Judit Varkonyi, Enrico Orciuolo, Charles Dumontet, Federica Gemignani, Anna Maria Rossi, Stefano Landi, Mario Petrini, Richard S. Houlston, Kari Hemminki, Federico Canzian. Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. *BJH*, 2012,158(4):515-8.
39. A. J. Vangsted, Tobias W. Klausen, Anne O. Gang, Niels Abildgaard, Niels F. Andersen, Peter Gimsing, Henrik Gregersen, Bjørn A. Nexø, Ulla Vogel, Peter Schwarz, Niklas Rye Jørgensen. Single nucleotide polymorphism in the P2X7 receptor and influence on outcome in patients with multiple myeloma. *Eur. J. Haematol.* 2014. 96 (2), 174-176.
40. Alessandro Martino, Daniele Campa, Artur Jurczynszyn, Joaquín Martínez-López, Felipe de Arriba de la Fuente, Judit Varkonyi, Charles Dumontet, Ramón García-Sanz, Federica Gemignani, Krzysztof Jamrozak, Manuel Jurado, Stefano Landi, Anna Maria Rossi, Fabienne Lesueur, Herlander Marques, Marek Dudziński, Marzena Wątek, Victor Moreno, Enrico Orciuolo, Mario Petrini, Rui Manuel Reis, Rafael Ríos, Juan Sainz, Ulla Vogel, Gabriele Buda, Annette Juul Vangsted, Federico Canzian. Genetic variations and multiple myeloma risk: IMMEnSE validation of the best reported associations. An extensive replication of the associations from the candidate-gene era. *Cancer Epidemiology, Biomarkers & Prevention*, 2014. 23(4), 670-674.
41. Niels Andersen , Ulla Vogel, Tobias Klausen, Peter Gimsing, Henrik Gregersen, Niels Abildgaard, Annette Vangsted. Polymorphisms in the heparanase (HSPE) gene in multiple myeloma - association with bone morbidity and Survival. *Eur J Haematol.* 2014 Jun 21. doi: 10.1111/ejh.12401
42. Stephen W. Erickson, Vinay R. Raj, Owen W. Stephens, Ishwori Dhakal, Shweta S. Chavan, Naveen Sanathkumar, Elizabeth Ann Coleman, Jeannette Y. Lee, Julia A. Goodwin, Senu Apewokin, Daohong Zhou, Joshua Epstein, Christoph J. Heuck, Annette

J. Vangsted. Genome-wide scan identifies variants in 2q12.3 and 9q22.33 associated with risk of multiple myeloma. *Blood*. 2014 Sep 18;124(12).

43. Daniele Campa, Alessandro Martino, Judit Varkonyi, Fabienne Lesueur, Krzysztof Jamrozik, Stefano Landi, Artur Jurczyszyn, Herlander Marques, Vibeke Andersen, Manuel Jurado, Hermann Brenner, Mario Petrini, Ulla Vogel, Ramón García-Sanz, Gabriele Buda, Federica Gemignani, Rafael Ríos, Annette Juul Vangsted Charles Dumontet, Joaquín Martínez-López, María José Moreno, Anna Stępień, Marzena Wątek, Victor Moreno, Aida Karina Dieffenbach, Anna Maria Rossi, Katja Butterbach, Svend E. Hove Jacobsen, Hartmut Goldschmidt, Juan Sainz, Jens Hillengass, Enrico Orciuolo, Marek Dudziński, Nils Weinhold, Rui Manuel Reis, Federico Canzian. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. *Int J Cancer*. 2015 Mar 1;136(5):E351-8. doi: 10.1002/ijc.29101.
44. Elizabeth Ann Coleman, Jeannette Y Lee, Stephen W. Erickson, Julia A. Goodwin, Marjorie L. Beggs, Naveen Sanathkumar, Daohong Zhou, Kent D. McKelvey, Vinay R. Raj, Senu Apewokin, Owen Stephens, Carol A. Enderlin, Annette Juul Vangsted, Patty Reed, Elias J. Anaissie. Chemotherapy-Induced Oral Mucositis: 11 SNPs Implicated In GWAS of 972 Patients With Multiple Myeloma. *Support Care Cancer*. 2015 Mar;23(3).
45. Morten O. Holmström, Peter Gimsing, Niels Abildgaard, Niels F. Andersen, Carsten Helleberg, Niels Aage T. Clausen, Tobias W. Klausen, Mikael Frederiksen, Dan L. Kristensen, Herdis Larsen, Per T. Pedersen, Torben Plesner, Robert Schou Pedersen, Bo Amdi Jensen, Henrik Gregersen, Annette J. Vangsted. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database. *Am J Hematol*. 2015 Apr;90(4):E73-4. doi: 10.1002/ajh.23932.
46. A. Vangsted. High-risk myeloma. *Best Practice*. 2015
47. Bhairavi Swaminathan, Gudmar Thorleifsson, Magnus Jöud, Mina Ali, Ellinor Johnsson, Ram Ajore, Patrick Sulem, Britt-Marie Halvarsson, Thorunn Rafnar, Daniel F Gudbjartsson, Guðmundur Eyjolfsson, Vilhelmina Haraldsdóttir, Christina Hultman, Erik Ingelsson, Sigurður Yngvi Kristinsson, Stig Lenhoff, Gisli Masson, Ulf-Henrik Mellqvist, Robert Månsson, Sven Nelander, Helga Ogmundsdóttir, Isleifur Olafsson, Olof Sigurðardóttir, Hlíf Steingrimsdóttir, Annette Juul Vangsted, Ulla Vogel, Anders Waage, Hareth Nahi, Ingemar Turesson, Kári Stefánsson, Urban Gullberg, Unnur Thorsteinsdóttir, Markus Hansson, Björn Nilsson. Variants in *ELL2* influencing immunoglobulin levels associate with multiple myeloma. *Nature Communication*, 6, 7213, 2015.

48. Rios,R.; Lupianez,C.B.; Campa,D.; Martino,A.; Martinez-Lopez,J.; Martinez-Bueno,M.; Varkonyi,J.; Garcia-Sanz,R.; Jamroziak,K.; Dumontet,C.; Cayuela,A.J.; Wetek,M.; Landi,S.; Rossi,A.M.; Lesueur,F.; Reis,R.M.; Moreno,V.; Marques,H.; Jurczynszyn,A.; Andersen,V.; Vogel,U.; Buda,G.; Orciuolo,E.; Jacobsen,S.E.; Petrini,M.; Vangsted,A.J.; Gemignani,F.; Canzian,F.; Jurado,M.; Sainz,J. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. *Endocr. Relat. Cancer.* 22,4, 545-559, 2015.
49. Elad Ziv, Eric Dean, Donglei Hu, Scott Huntsman, Jennifer Caswell, Blake Aftab,Laura Fejerman, Paige Bracci, Clinicians: Jeffrey Wolf, Thomas Martin, Celine Vachon, Susan Slager, Daniel Serie, Alexandra Greenberg, Vincent Rajkumar, Shaji Kumar, Federico Canzian, Alessandro Martino, Daniele Campa; Gabriele Buda, Krzysztof Jamroziak, Juan Sainz Perez, Charles Dumontet, Herlander Marques, Annette Juul Vangsted, Artur Jurczynszyn, Marek Dudziński, Marek Dudziński, Joaquin Martinez. Genome wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. *Nature Communication*, 6, 7539, 2015.
50. Kathrine Schmidt, Annette J. Vangsted, Bettina Hansen, Ulla Vogel, Ulla Vogel, Emil. U. Hermansen, Sara B. Jensen, Magdalena J. Laska, Bjørn A. Nexø. Synergy of two human endogenous beta-and gamma-retroviruses in Multiple myeloma. *Leuk Res.* 2015 Oct;39(10):1125-8
51. Stephen W. Erickson, Owen W. Stephens, Shweta S. Chavan, Naveen Sanathkumar, Erming Tian, Joshua Epstein, Bart Barlogie, Christoph J. Heuck, Annette J. Vangsted Common Genetic Variants in 11q13.3 and 9q22.33 Are Associated With Molecular Subgroups of Multiple Myeloma. *Leukemia.* 2015 Dec;29(12):2418-21
52. Stephen W. Erickson, Owen W. Stephens, Shweta S. Chavan, Naveen Sanathkumar, Joshua Epstein, Bart Barlogie, Christoph J. Heuck, Annette J. Vangsted. A common genetic variant in 19q13.3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3. *Br J Haematol.* 2016 Sep;174(6):991-3.
53. Rasmus Sørrig, Tobias W Klausen, Morten Salomo; Annette J Vangsted, Brian Østergaard, Henrik Gregersen, Ulf Christian Frølund, Niels F Andersen, Carsten Helleberg, Kristian T Andersen, Robert S Pedersen, Per Pedersen, Niels Abildgaard and Peter Gimsing for the Danish Myeloma Study Group. A population based study of smoldering multiple myeloma in Denmark. Risk factors for progression and overall survival. *Eur J Haematol.* 2016 Sep;97(3):303-9

54. Niels Emil Ulrich Hermansen, Rehannah Borup, Mette Klarskov Andersen, Annette Juul Vangsted, Nielsaage Tøffner Clausen, Dan Lennart Kristensen, Finn Cilius Nielsen, Peter Gimsing. Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray translation. *Int J Lab Hematol*. 2016 Jun;38(3):298-307.
55. Peter Gimsing, Morten Holmstrøm, Tobias Wirenfelt Klausen, Niels Frost Andersen, Henrik Gregersen, Robert Schou Pedersen, Torben Plesner, Per Trøllund Pedersen, Mikael Frederiksen, Ulf Frølund, Carsten Helleberg, Annette Vangsted, Peter de Nully Brown and Niels Abildgaard¹. The Danish National Multiple Myeloma Registry. *Clin Epidemiol*. 2016 Oct 25;8:583-587
56. Jonathan S. Mitchell, Ni Li, Niels Weinhold, Asta Försti, Mina Ali, Mark van , Gudmar Thorleifsson, David C. Johnson, Bowang Chen, Britt-Marie Halvarsson, Daniel F. Gudbjartsson, Rowan Kuiper, Owen W. Stephens, Uta Bertsch, Peter Broderick, Chiara Campo, Hermann Einsele, Walter A. Gregory, Urban Gullberg, Marc Henrion, Jens Hillengass, Per Hoffmann, Graham H. Jackson, Ellinor Johnsson, Magnus Jöud, Sigurður Y. Kristinsson, Stig Lenhoff, Oleg Lenive, Ulf-Henrik Mellqvist, Gabriele Migliorini, Hareth Nahi, Sven Nelander, Jolanta Nickel, Markus M. Nöthen, Thorunn Rafnar, Fiona M. Ross, Miguel Inacio da Silva Filho, Bhairavi Swaminathan, Ingemar Turesson, Annette Vangsted, Ulla Vogel, Anders Waage, Brian A. Walker, Anna-Karin Wihlborg, Annemiek Broijl, Faith E. Davies, Unnur Thorsteinsdottir, Christian Langer, Markus Hansson, Martin Kaiser, Pieter Sonneveld, Kari Stefansson, Gareth J. Morgan, Hartmut Goldschmidt, Kari Hemminki, Björn Nilsson, Richard S. Houlston. A genome-wide association study identifies multiple susceptibility loci for multiple myeloma. *Nat Commun*. 2016 Jul 1;7:12050.
57. Rafael Ríos-Tamayo, Carmen Belén Lupiáñez^{*}, Daniele Campa, Thomas Hielscher, Niels Weinhold, Joaquin Martínez-López, Andrés Jerez Cayuela, Stefano Landi, Krzysztof Jamrozak, Charles Dumontet, Marzena Wątek, Fabienne Lesueur, Rui Manuel Reis, Herlander Marques, Artur Jurczynszyn, , Ulla Vogel, Gabriele Buda, Ramón García-Sanz, Enrico Orciuolo, , Mario Petrini, Annette J Vangsted, Federica Gemignan, Asta Försti, Hartmut Goldschmidt³, Kari Hemminki, Federico Canzian, Manuel Jurado, Juan Sainz. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. *Oncotarget*. 2016 Jul 18
58. Angelica Macaudo, Diego Calvetti, Giuseppe Maccari, Kari Hemminki, Asta Försti, Hartmut Goldschmidt, Niels Weinhold, Richard Houlston, Vibeke Andersen, Ulla Vogel, Gabriele Buda, Judit Varkonyi Anna Sureda, Joaquin Martinez Lopez, Marzena Watek, Aleksandra Butrym, Maria Eugenia Sarasquete, Marek Dudziński, Artur Jurczynszyn, Agnieszka Druzd-Sitek Marcin Kruszewski, Edyta Subocz, Mario Petrini, Elzbieta

Iskierka-Jażdżewska, Malgorzata Rażny, Gergely Szombath, Herlander Marques, Daria Zawirska, Dominik Chraniuk, Janusz Halka, Svend Erik Hove Jacobsen, Grzegorz Mazur, Ramón García Sanz, Charles Dumontet, Victor Moreno, Anna Stępień, Katia Beider, Matteo Pelosini, Rui Manuel Reis, Malgorzata Krawczyk-Kulis, Marcin Rymko, Hervé Avet-Loiseau, Fabienne Lesueur, Norbert Grząsko, Olga Ostrovsky, Krzysztof Jamroziak, Annette J. Vangsted, Andrés Jerez, Waldemar Tomczak, Jan Maciej Zaucha, Katalin Kadar, Juan Sainz Pérez, Arnon Nagler, Stefano Landi, Federica Gemignani, Federico Canzian. Identification of mirSNPs associated with the risk of multiple myeloma. *Int J Cancer*. 2017 Feb 1;140(3):526-534

59. Kaspar René Nielsen, Maria Rodrigo-Domingo, Rudi Steffensen, John Baech, Kim S. Bergkvist, Liesbeth Oosterhof, Ulla Vogel, Annette Vangsted, Alexander Schmitz, Julie Støve Bødker, Preben Johansen, Karen Dybkær, Martin Bøgsted, Hans Erik Johnsen. Interaction between inherited inflammatory genes are associated with multiple myeloma disease risk and survival. *Leuk Lymphoma*. 2017 Apr 9:1-10.
60. Henrik Gregersen, Annette Juul Vangsted, Niels Abildgaard, Peter Gimsing, Niels Frost Andersen, Robert Schou Pedersen, Ulf Christian Frølund, Carsten Helleberg, Bettina Broch, Per Trøllund Pedersen, Tobias Wirenfeldt Klausen. The Impact of Comorbidity on Mortality in Multiple Myeloma: A Danish Nationwide Population-based Study. *Accepted Cancer Medicine*.
61. Kristian T. Andersen, Tobias W. Klausen, Niels Abildgaard, Mette K. Andersen, Niels F. Andersen, Ulf Frølund, Carsten Helleberg, Eigil Kjeldsen, Per T. Pedersen, Asta Svirskaitė, Birgitte Preiss, Peter Gimsing, Annette J. Vangsted. Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Database. *Accepted Am. J. Hematol*

Book: Effect of genetic variation on risk of disease and treatment effect in multiple myeloma patients. Annette Vangsted. 2012. ISBN-number 978-87-92895-00-4